Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family
that is abnormally activated in many epithelial tumors. Several mechanisms lead to the …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …

BACKGROUND: A phase 3 Radiation Therapy Oncology Group (RTOG) study subset
analysis demonstrated improved overall survival (OS) with the addition of stereotactic …

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the
most important targets for drug development in oncology. Monoclonal antibodies targeting …

Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB
receptor family that is abnormally activated in many epithelial tumors. The aberrant …

Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …

Molecular targeting strategies for cancer therapy are distinct from conventional
chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One …